PAION is a biopharmaceutical company based in Aachen, Germany (listed at Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need.

PAION’s activities are focused on the development of the three drugs Desmoteplase, Enecadin and Solulin. PAION’s leadproduct candidate, Desmoteplase, the most specific plasminogen activator known today, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus. Currently being tested in an international multi-centred Phase III study, Desmoteplase was successfully tested in two independent Phase II studies for the treatment of acute ischaemic stroke between 3 and 9 hours after onset of symptoms and has received fast-track designation from the U.S. Food and Drug Administration. Desmoteplase is partnered with Forest Laboratories, Inc. and H. Lundbeck A/S. Currently PAION employs more than 75 people.